Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIV007 in Neovascular Age-Related Macular Degeneration
NCT07557121Phase 2Recruiting
- Sponsor
- AiViva BioPharma
- Start
- Jul 2026
- Primary completion
- Jun 2027
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AIV007 in neovascular age-related macular degeneration (NVAMD), sponsored by AiViva BioPharma. Started Jul 2026; status: recruiting.
02
Drugs
AIV007
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07557121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07557121.